TC
CERE

Trium Capital’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Trium Capital’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-317,731
Closed -$13M – 88
2024
Q2 		$13M Buy
+317,731
New +$13.2M 1.64% 7

Other funds holding CERE

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

Trium Capital's CERE Position: Q3 2024 in Review

Trium Capital sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 317,731 shares — an estimated $13M sold.

Trium Capital first reported a position in CERE in Q2 2024 and held it in 1 quarter. The position peaked at $13M in Q2 2024. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

  • Trium Capital reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Trium Capital sold 317,731 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $13M.
  • Trium Capital first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q2 2024 and held it in 1 quarter.
  • Trium Capital's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $13M in Q2 2024.
  • 2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on Trium Capital's 13F filing for Q3 2024, filed 7 Oct 2024.